首页> 外文期刊>Acta Virologica: International Journal >Development of rabies DNA vaccine using a recombinant plasmid.
【24h】

Development of rabies DNA vaccine using a recombinant plasmid.

机译:使用重组质粒开发狂犬病DNA疫苗。

获取原文
获取原文并翻译 | 示例
           

摘要

A recombinant plasmid pTargeT.rabgp containing the glycoprotein (G) gene of Rabies virus (RV) was constructed and produced for immunogenicity studies on mice and dogs. The mice immunized twice with 50 microg or 100 microg of pTargeT.rabgp intramuscularly (i.m.), showed a serum antibody titer of 256 or 64, respectively 14 days post immunization (p.i.). When the vaccinated mice were challenged at 14 days p.i. with RV i.c., they were protected in 81.25% or 87.5%, respectively. A positive cell mediated immune response was observed by lymphocyte proliferation assay and macrophage migration inhibition test. These results indicate that the pTargeT.rabgp plasmid can be used as a rabies DNA vaccine.
机译:构建了包含狂犬病病毒(RV)糖蛋白(G)基因的重组质粒pTargeT.rabgp,并进行了小鼠和狗的免疫原性研究。在免疫后14天(i.m.)用50微克或100微克pTargeT.rabgp肌内(i.m.)免疫两次的小鼠分别显示出256或64的血清抗体效价(p.i.)。当接种小鼠在p.i第14天受到攻击时。在使用RV i.c.的情况下,它们分别获得了81.25%或87.5%的保护。通过淋巴细胞增殖测定和巨噬细胞迁移抑制试验观察到阳性细胞介导的免疫应答。这些结果表明pTargeT.rabgp质粒可用作狂犬病DNA疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号